The effect of natalizumab on disability score and relapse rate of multiple sclerosis patients: a prospective cohort study
Abstract Multiple sclerosis (MS) is a progressive immune-related disorder of the central nervous system leading to destruction of myelin sheaths. Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin which has been approved for treatment of relapsing forms of...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-11-01
|
| Series: | Clinical and Translational Medicine |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40169-018-0216-3 |